eFFECTOR Therapeutics (EFTR) Plunges 82% as NSCLC Study Fails

eFFECTOR Therapeutics, Inc. (EFTR) plunged 82% in the last trading session on Apr 4, after the company announced disappointing top-line results from the primary analysis of its mid-stage non-small cell lung cancer (NSCLC) study. Consequently, the company has abandoned the tomivosertib development program in frontline NSCLC.The randomized phase II KICKSTART study is evaluating the safety and efficacy of its investigational candidate, tomivosertib, in comparison with placebo, each administered in combination ...